Understanding predictive and prognostic markers
|
|
- Trevor Morgan
- 5 years ago
- Views:
Transcription
1 Understanding predictive and prognostic markers Professor Aimery de Gramont Chairman of ARCAD Foundation and GERCOR, Paris FRANCE
2 Understanding predictive and prognostic markers Aimery de Gramont
3 Prognostic marker Effect of marker on clinical endpoint M C Buyse, Eur J Cancer Suppl 5, 2007.
4 Chibaudel B, et al. The Oncologist 2011
5
6 QUASAR Results: Recurrence Score, T Stage, and MMR Deficiency are Key Independent Predictors of Recurrence in Stage II Colon Cancer Risk of recurrence at 3 years 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% Recurrence Score T4 stage (13%) T3 and MMR proficient (76%) MMR deficient (11%) Kerr D, ASCO 2009 O Connell JCO 2010
7 Predictive marker Trt Effect of treatment on clinical endpoint depends on the marker M C Buyse, Eur J Cancer Suppl 5, 2007.
8 HER2 and trastuzumab mechanism of action trastuzumab HER2 receptor Trastuzumab Inhibits HER2-mediated signalling in HER2-positive tumors Prevents HER2 activation by blocking extracellular domain cleavage Activates antibody-dependent cellular cytotoxicity
9 TOGA Herceptin gastric Cancer. Primary end point: OS Event FC + T FC Events Median OS HR % CI 0.60, 0.91 p value Time (months) No. at risk T, trastuzumab Van Cutsem E. ASCO 2009 Bang YJ, et al. Lancet
10 Crizotinib in locally advanced or metastatic ALK-positive lung cancer Shaw, et al. NEJM 2013
11 Epidermal growth factor receptor (EGFR) and KRAS Khambata-Ford S, et al. J Clin Onc 2007;25:3230 7
12 Relating KRAS status to efficacy: PFS Cetuximab + FOLFIRI HR=0.63; p=0.007 mpfs wild-type (n=172): 9.9 months mpfs mutant (n=105): 7.6 months FOLFIRI HR=0.97; p=0.87 mpfs wild-type (n=176): 8.7 months mpfs mutant (n=87): 8.1 months Progression-free survival estimate Cetuximab + FOLFIRI mutant Cetuximab + FOLFIRI wild-type FOLFIRI mutant FOLFIRI wild-type Months Months Van Cutsem E, et al. ASCO 2008
13 Enrichment strategy (PRIME study) KRAS 1 RAS 2 RAS/RAF 2 KRAS MT KRAS WT RAS MT RAS WT RAS/RAF MT RAS/RAF WT 40% 60% 51.7% 48.3% 57.4% 42.6% (KRAS exon 2) KRAS WT: n=656 KRAS MT: n=440 (KRAS Ascertainment rate 93%) (KRAS/NRAS exon 2,3,4) RAS WT: n=512 RAS MT: n=548 (RAS Ascertainment rate 90%) (KRAS/NRAS exon 2,3,4; BRAF exon 15) RAS/RAF WT: n=446 RAS/RAF MT: n=601 1 Douillard JY, et al. J Clin Oncol 2010; 28: ; 2 Oliner K, et al. ASCO 2013 #3511.
14 DFS in dmmr patients, pooled data Stage II (N=102) Stage III (N=63) % Disease Free Years Untreated 87% Treated 72% HR: 2.80 ( ) p=0.05 % Disease Free Years 5 yr DFS 5 yr DFS Untreated 62% Treated 67% HR: 1.08 ( ) p=0.86 Sargent, JCO 2009
15 CRC biomarkers classification Metastatic KRAS Adjuvant MMR WT Mutant dmmr pmmr BRAF NRAS. codon gene signature
16 Molecular Classification of CRC Molecular Classification of Colon Cancer Stage II-III Salazar, et al. ASCO 2013
17 Surrogate marker Effects of treatment Surrogate on surrogate and true Trt and on true endpoint S endpoint must be T must be correlated correlated Buyse et al, Biostatistics 2000;1:49; Gail, Pfeiffer and van Houwelingen, Biostatistics 2000;1:231.
18 PFS as a surrogate marker for OS Correlation between Experimental 5FU PFS hazard ratio and OS hazard PFS Association between PFS and OS Overall survival ratio Buyse et al, JCO 2007; 25: 5218.
19 ACCENT: 3yr DFS vs 5yr OS 1,3 1,2 1,1 HR for 5 Year OS 1 0,9 0,8 R 2 = ,7 0,6 May 2004: ODAC recommends 3-yr DFS as new regulatory endpoint for FULL approval in adjuvant colon cancer 0,5 0,5 0,6 0, ,8 July 2013, Barcelona 0,9 1 1,1 1,2 1,3 HR for 3 Year DFS
20 Median number of patients in trials FU infusion Mayo Regimen 5FU HD infusion
21 Median number of patients in trials Raltitrexed Irinotecan Irinotecan Oxaliplatin Capecit. Capecit.
22 Median number of patients in trials Bevacizu. Bevacizu. PTK Cetux Panitumu. Panitumu.
23 Median number of patients in trials Targeted Therapies FU New Chemotherapy 0 2 trials are needed for first registration
24 Sample size and hazard-ratio (HR) 1200 Sample size and HR α sided β 0.80 Acrual 24m Follow-up 36m Median PFS 9m Sample Size HR
25 The requirement that new agents be demonstrated to be safe and effective before marketing approval is granted has led to a traditional paradigm for drug development that typically requires thousands of patients, hundreds of millions of dollars, and >1 decades to fulfill. Unless this paradigm is changed, there will not be enough patients, money, or time available to evaluate all of the promising new anticancer agents in development. New clinical trial designs and end points are necessary to permit more efficient evaluation of putative cancer treatments so that the most promising agents can move forward quickly, while disappointing agents are rapidly identified and discarded. Schilsky RL. Clin Cancer Res 2002, 8:935-8
26 Studies Received to Date Study Group P I Number of Patients E3200 ECOG Giantonio 820 BICC-C Pfizer Fuchs / Rothenberg 547 AVF2107g Hurwitz 923 NO16966 Cassidy / Saltz 2035 Roche/GNE N Rothenberg 627 AVF2192 Kabbinavar 209 N9741 NCCTG / Sanofi Goldberg 795 NCIC CO.17 NCIC-CTG Jonker 572 OPTIMOX 1&2 Tournigand 823 C97-3 GERCOR Tournigand 226 C181 Peeters/ 1186 Van Cutsem PRIME (C203) Amgen Douillard 1183 PACCE (C249) Hecht 1054 C July 2013, Van Barcelona Cutsem
27 Studies Received to Date Study Group P I Patients CAIRO 1&2 DCCG Punt 1575 COIN Maughan 2445 FOCUS1 & FOCUS2 MRC (UK) Seymour 2577 MACRO Diaz Rubio / Aranda TTD-01 TTD Diaz Rubio / Aranda 342 MAX AGITG Niall Tebbutt 471 HORG HORG Souglakos 283 GONO GONO Falcone 244 N9841 NCCTG Pitot 491 AIO 22 Porschen 474 FIRE II (CIOX) AIO 177 HORIZON II 1076 HORIZON III AZ Hoff/Schmoll 1601 BOND MERCK Cunningham 329 Total 24,028 Studies recently added shown in boldface 27
28 Results Trial Level PFS vs. OS 28 28
29 Early objective response 29
30 30
31 Conclusions Type of marker: Identification Validation Goal Prognostic Easy, but often flawed Frequent, but often disappointing Helpful for therapeutic strategy Predictive Hard, needs randomized trial Very rare, needs large randomized trial Avoids ineffective therapy Decreases cost Surrogate Hard, needs metaanalysis or large randomized trial Very rare, needs large randomized trial Faster results, smaller population Decreases cost
32
Colon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationThe role of Maintenance treatment Appropriate endpoints according to ESMO consensus
ESMO Preceptorship Programme Colorectal Cancer Singapore-October 20-22 2016 JY Douillard, MD, PhD, CMO ESMO The role of Maintenance treatment Appropriate endpoints according to ESMO consensus MAINTENANCE
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationWhat s New? Dr. Barbara Melosky
Metastatic Colorectal o Carcinoma a What s New? Dr. Barbara Melosky Objectives Review any recent changes regarding treatment t t options for mcrc Discuss the common and expected toxicities of treatment
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationRECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER
RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS
More informationTHE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER
THE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Dept of GI Medical Oncology November 5, 2010
More informationKonzepte bei der Therapie des metastasierten kolorektalen Karzinoms
21. Ärzte Fortbildungskurs in Klinischer Onkologie 24.-26. Februar 2011 Kantonspital St. Gallen / Schweiz Konzepte bei der Therapie des metastasierten kolorektalen Karzinoms Claus-Henning Köhne Klinik
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationReview of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux
Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux 2 ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working groups E Van Cutsem A Sobrero
More informationPage: 1 of 17. KRAS, NRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer
Page: 1 of 17 Last Review Status/Date: March 2015 Analysis in Metastatic Colorectal Cancer Description This policy summarizes the evidence for using tumor cell KRAS, NRAS and BRAF mutational status as
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationMOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators
MOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators Thierry André, Armand de Gramont, Benoist Chibaudel, Annemilaï Raballand,
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationValidated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD
Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationWhat to do after 1st-line failure in mcrc?
What to do after 1st-line failure in mcrc? Werner Scheithauer Univ.Klinik für Innere Med. I & CCC, Med.Uni.Wien-AKH mcrc front-line treatment strategy today Updated results of head-to-head trials in mcrc,
More informationDr. Iain Tan. Senior Consultant GI Medical Oncologist National Cancer Centre Singapore
ESMO-ASIA 2017 Preceptorship (GI cancers) Session: Metastatic colorectal cancer, liver limited metastases Topic: Unresectable or borderline resectable : chemotherapy +/- targeted agents Dr. Iain Tan Senior
More informationOncologist. The. Gastrointestinal Cancer
The Oncologist Gastrointestinal Cancer The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationColorectal cancer is the second most common cause of
SYSTEMIC TREATMENT FOR METASTATIC COLORECTAL CANCER Systemic Treatment: Maintenance Compared with Holiday Cornelis J.A. Punt, MD, PhD, Lieke H.J. Simkens, MD, and Miriam Koopman, MD, PhD OVERVIEW With
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: KRAS, NRAS, and BRAF Variant Analysis
More informationTargeted therapies in colorectal cancer: the dos, don ts, and future directions
Editorial Targeted therapies in colorectal cancer: the dos, don ts, and future directions Marwan Fakih City of Hope Comprehensive Cancer Center, 1500 E Duarte St, Duarte, CA 91010, USA Corresponding to:
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationRelated Policies None
Medical Policy MP 2.04.53 BCBSA Ref. Policy: 2.04.53 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 3 September 2014 VECTIBIX, 20 mg/ml, concentrate for solution for infusion B/1 5 ml vial (CIP: 34009 571 818 5 7)
More informationAshita Waterston Beatson West of Scotland Cancer Centre
Ashita Waterston Beatson West of Scotland Cancer Centre Aim of treatment Scheduling and choice of treatments are dictated by aim: Down staging for resectability: upfront intensive Prolong survival: combination
More informationKRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer
KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer Policy Number: 2.04.53 Last Review: 5/2018 Origination: 1/2011 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationclinical practice guidelines
Annals of Oncology 21 (Supplement 5): v93 v97, 2010 doi:10.1093/annonc/mdq222 Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment E. Van Cutsem 1, B. Nordlinger 2 & A. Cervantes
More informationQ11: WHAT IS THE CURRENT STANDARD FIRST LINE TREATMENT FOR METASTATIC INOPERABLE COLORECTAL CANCER?
Q11: WHAT IS THE CURRENT STANDARD FIRST LINE TREATMENT FOR METASTATIC INOPERABLE COLORECTAL CANCER? Version 11/24/2011 3:08 PM Q11 TABLE OF CONTENTS SCIENTIFIC REPORT... 6 1 INTRODUCTION... 6 1.1 PICO...
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationTherapy for Metastatic Colorectal Cancer
Therapy for Metastatic Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Learning Objectives Key
More informationAnnals of Oncology Advance Access published August 12, 2014
Annals of Oncology Advance Access published August 12, 2014 1 Extended RAS mutations and anti-egfr monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationBest of ASCO 2009 / GI
Best of ASCO 2009 / GI Santa Monica, CA J. Randolph Hecht, M.D. Professor of Clinical Medicine Director, UCLA GI Oncology Program David Geffen School of Medicine at UCLA Financial Disclosures I have no
More informationTreatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations
Treatment of the elderly metastatic colorectal cancer patient: SIOG Recommendations D Papamichael MB BS FRCP On behalf of the SIOG CRC in the Elderly Task Force Madrid 10/11/07 8 th Meeting of the International
More informationCOLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
More informationContemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer
Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer Kanwal Raghav, MD, and Cathy Eng, MD Abstract The existing therapeutic armamentarium for first-line treatment of metastatic
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationTHE BEST OF ESMO 2016
THE BEST OF ESMO 2016 Colorectal cancer Pr Julien TAIEB, Sorbonne Paris Cité and Paris Descartes University Georges Pompidou European Hospital Paris, FRANCE esmo.org DISCLOSURES JT has received research
More informationProgress towards an individualized approach to therapy: colorectal cancer
Progress towards an individualized approach to therapy: colorectal cancer Alan P. Venook, M.D. University of California, SF GIST: PET change after 4 weeks imatinib Multiple liver and upper abdominal 18
More informationThe ESMO consensus conference on metastatic colorectal cancer
ESMO Preceptorship Programme Colorectal cancer Prague July, 6-7 2016 The ESMO consensus conference on metastatic colorectal cancer Andres Cervantes ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working
More informationBasket Trials: Features, Examples, and Challenges
: Features, s, and Challenges Lindsay A. Renfro, Ph.D. Associate Professor of Research Division of Biostatistics University of Southern California ASA Biopharm / Regulatory / Industry Statistics Workshop
More informationMetastatik Kolorektal Kanser Tedavisinde Yeni Biyobelirteçler Sonrası Panitumumab. Prof. Dr. N. Faruk Aykan Antalya 22 Mart 2014
Metastatik Kolorektal Kanser Tedavisinde Yeni Biyobelirteçler Sonrası Panitumumab Prof. Dr. N. Faruk Aykan Antalya 22 Mart 2014 1952-1953 St. Louis, ABD Kinase growth factor pathway Activated receptor
More informationChemotherapy re-challenge response rate in metastatic colorectal cancer
Original Article Chemotherapy re-challenge response rate in metastatic colorectal cancer Alexandra E. Chambers 1, Jacob Frick 1, Natalee Tanner 1, Richard Gerkin 2, Madappa Kundranda 3, Tomislav Dragovich
More informationANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria
IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,
More informationCitation for final published version: Publishers page: <http://dx.doi.org/ /annonc/mdw645>
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/102643/ This is the author s version of a work that was submitted to / accepted
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationAdjuvant therapy in older adults: controversies and challenges - Colorectal cancer -
International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie
More informationREVIEW ON THE ESMO CONSENSUS CONFERENCE ON ADVANCED COLORECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 REVIEW ON THE ESMO CONSENSUS CONFERENCE ON ADVANCED COLORECTAL CANCER Andrés Cervantes Professor of Medicine Strategic changes
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationKRAS G13D mutation testing and anti-egfr therapy
KRAS G13D mutation testing and anti-egfr therapy KRAS G13D mutation and anti-egfr therapy Current data do not support a need to specifically identify this mutation for assessing anti-egfr eligibility in
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Panitumumab (Vectibix ) for the first-line treatment of metastatic colorectal cancer DSD: Horizon Scanning in Oncology Nr. 011 ISSN online 2076-5940 Horizon Scanning in Oncology
More informationSURROGATE ENDPOINTS IN ONCOLOGY: OBJECTIVES, METHODOLOGICAL OVERVIEW, AND CURRENT STATUS
SURROGATE ENDPOINTS IN ONCOLOGY: OBJECTIVES, METHODOLOGICAL OVERVIEW, AND CURRENT STATUS Everardo D. Saad, MD Medical Director, IDDI everardo.saad@iddi.com Acknowledgement to Marc Buyse 1 The ideal endpoint
More informationPanitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd
Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationBalancing the efficacy and toxicity of chemotherapy in colorectal cancer
Therapeutic Advances in Medical Oncology Review Balancing the efficacy and toxicity of chemotherapy in colorectal cancer Michael S. Braun and Matthew T. Seymour Ther Adv Med Oncol (2011) 3(1) 43 52 DOI:
More informationK-Ras mutational status and response to EGFR inhibitors for treatment of advanced CRC. Monica Bertagnolli, MD. CRA Continuing Education, November 2008
K-Ras mutational status and response to EGFR inhibitors for treatment of advanced CRC Monica Bertagnolli, MD CRA Continuing Education, November 2008 The Ras Oncogene Kirsten and Harvey: 1964 Identification
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationCOLORECTAL CANCER: STATE OF THE ART
COLORECTAL CANCER: STATE OF THE ART Andrés Cervantes Professor of Medicine DECLARATION OF INTERESTS Consulting and advisory services, speaking or writing engagements, public presentations Merck Serono
More informationJ Cancer Res Clin Oncol (2014) 140: DOI /s
J Cancer Res Clin Oncol (2014) 140:1607 1614 DOI 10.1007/s00432-014-1678-3 Original Article Clinical Oncology Left sided primary tumors are associated with favorable prognosis in patients with KRAS codon
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationMetastatic Colorectal Cancer. Update 2015
Metastatic Colorectal Cancer Update 2015 A/Prof Jeremy Shapiro GI Medical Oncologist Cabrini Hospital, Melbourne 1 Not all pts with metastatic CRC are equal 1 st consideration can patient be cured by resection
More informationAvailable at journal homepage:
European Journal of Cancer (212) 48, 1466 1475 Available at www.sciencedirect.com journal homepage: www.ejconline.com Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationReprint requests: American Society of Clinical Oncology Mill Road, Suite 800. Alexandria, VA
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti Epidermal Growth Factor
More informationGI SLIDE DECK. Selected abstracts from: 31 May 4 Jun 2013 Chicago, USA ASCO Annual Meeting. 27 Sep 1 Oct 2013 Amsterdam, Netherlands ESMO-ECCO
GI SLIDE DECK 31 May 4 Jun 2013 Chicago, USA ASCO Annual Meeting 2013 Selected abstracts from: 3 Jul 6 Jul 2013 Barcelona, Spain WCGIC 27 Sep 1 Oct 2013 Amsterdam, Netherlands ESMO-ECCO Supported by Eli
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationUpdate on Chemotherapy for Advanced Colorectal Cancer
Review Article [1] March 02, 2001 By Daniel G. Haller, MD [2] Efforts to improve the length and quality of life, as well as to expand treatment options, for patients with metastatic colorectal cancer have
More information/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W
癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationProgress and Challenges in the Adjuvant Treatment of Stage II & III Colon Cancer
Progress and Challenges in the Adjuvant Treatment of Stage II & III Colon Cancer Professor Eva Segelov Monash Health and Monash University (with thanks to A/P Jeremy Shapiro) Melbourne, Australia Apr 2017
More informationPopulations Interventions Comparators Outcomes Individuals: With metastatic colorectal cancer
Metastatic Colorectal Cancer (20453) Medical Benefit Effective Date: 07/01/17 Next Review Date: 05/18 Preauthorization Yes Review Dates: 05/12, 05/13, 05/14, 05/15, 05/16, 07/16, 05/17 Preauthorization
More informationVectibix. Vectibix (panitumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix
More informationKolorektalni karcinom- novosti u liječenju. PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić
Kolorektalni karcinom- novosti u liječenju PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić Kolorektalni karcinomnovosti u liječenju PANEL : Maja Banjin, Janja Ocvirk, Borislav
More informationCURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES
CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli
More informationMANAGEMENT OF ADVANCED COLORECTAL CANCER
MANAGEMENT OF ADVANCED COLORECTAL CANCER Alberto Sobrero IRCCS San Martino IST Genoa Italy Disclosures : Pfizer, Roche, Merck, Amgen, Celgene, Bayer, Sanofi, Nordic, Takeda,BMS, Syrtex, Servier outline
More informationWhat to do after 1 st line failure?
ESMO Preceptorship Programme Colorectal Cancer Singapore 20-22 nd 2016 JY Douillard MD PhD ESMO CMO What to do after 1 st line failure? mcrc: How to maximize survival? Improving 1st line therapy efficacy
More information1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)
1 st LINE ANTI-VEGF TREATMENT OF METASTATIC COLORECTAL CANCER (CRC) Role of the VEGF Pathway in Oncogenesis The Role of Angiogenesis in Cancer Somatic mutation Small avascular tumor Tumor secretion of
More informationMEDICAL POLICY. SUBJECT: GENOTYPING - RAS MUTATION ANALYSIS IN METASTATIC COLORECTAL CANCER (KRAS/NRAS) POLICY NUMBER: CATEGORY: Laboratory
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationNovel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer. Objectives
Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer Michael S. Lee, MD Assistant Professor of Medicine University of North Carolina Objectives Discuss important clinicopathologic
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationAntiangiogenic therapy in GI cancer: current status and future directions
Riccardo Giampieri, MD, PhD Università Politecnica delle Marche Ospedali Riuniti diancona Antiangiogenic therapy in GI cancer: current status and future directions Before starting Summary - Antiangiogenesis
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationThe Use of Epidermal Growth Factor Receptor Inhibitors in Advanced Colorectal Cancer
CED-CCO Special Advice Report 8 EDUCATION AND INFORMATION 2012 The Use of Epidermal Growth Factor Receptor Inhibitors in Advanced Colorectal Cancer D. Jonker, J. Biagi, and A.E. Haynes Report Date: July
More information